The mammalian target of rapamycin (mTOR) was already an established player in cell growth when a discovery late in 2004 stepped up interest in the molecule. TOR was originally found as a target to rapamycin, a drug used to suppress tissue-graft rejection, that was also found to have some tantalizing antitumor effects. The discovery of a rapamycin-insensitive TOR pathway in 2002 in yeast didn't quash the name of the protein, but rather led to the realization that mTOR exists in two distinct multiprotein complexes, mTORC1 and mTORC2.
Advertisement
Survey Series
For Advertisers
For mTOR, Clarification and Confusion
A double life for the target of rapamycin muddies its role in cancer
|
|||||||||
|
|||||||||
|
